{
  "docId": "019de074-15c9-703f-ba69-83bd63385db9",
  "docSlug": "61dc585c6c50f6919636d426c025da60",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 42,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide summarizes the primary outcomes of the SERENA-2 trial, confirming PFS benefits and safety, and mentions ongoing Phase III trials (SERENA-4 and SERENA-6).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-15c9-703f-ba69-83bd63385db9/29",
  "deckHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9",
  "deckJsonHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9.json",
  "deckAnchorHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.13,
        "w": 0.932,
        "x": 0.034,
        "y": 0.695
      },
      "kind": "callout",
      "text": "SERENA-2 results support the further development of camizestrant in ER+ breast cancer, ongoing enrolment Phase III SERENA-4 and SERENA-6 trials",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3df7d882-04ad-47db-8d78-74a1dff395f4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.38,
        "w": 0.918,
        "x": 0.041,
        "y": 0.27
      },
      "kind": "list",
      "text": "SERENA-2 met its primary objective: camizestrant at both 75 and 150 mg doses improves PFS over fulvestrant in post-menopausal women with ER+/HER2- ABC. Camizestrant delivers statistically significant and clinically meaningful PFS benefit at both 75 and 150 mg doses over fulvestrant in the overall population. A clinically meaningful PFS benefit was observed across the pre-specified subgroups of unmet medical need (post-CDK4/6i, lung/liver metastases, ESR1m and evidence of ER-driven disease). Both camizestrant doses are well tolerated, with infrequent Grade ≥3 TRAEs, dose reductions and discontinuations.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "473ab3cd-b055-454f-8aed-543acd4b48ea",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.85,
        "x": 0.076,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "aSERENA-4 NCT04711252; bSERENA-6 NCT04964934 ABC: advanced breast cancer; AE: adverse event; CDK4/6i: CDK4/6 inhibitor; ESR1m: mutation in estrogen receptor 1 gene; HER2: human epidermal growth factor receptor 2; PFS: progression-free survival; TRAE: treatment-related adverse event. This presentation is the intellectual property of the author/presenter. Contact them at moliveira@vhio.net for permission to reprint and/or distribute.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7cbf96b7-08e4-4bb5-8539-0d829f9ca1ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.065,
        "w": 0.38,
        "x": 0.034,
        "y": 0.065
      },
      "kind": "title",
      "text": "SERENA-2: conclusions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea63d7d3-59ac-46f4-8499-e42725a1edd5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "485ac933-29d0-4dc1-809d-6cd2f6034302",
      "evidence": "list/bullet: SERENA-2 met its primary objective: camizestrant at both 75 and 150 mg doses improves PFS over fulvestrant in post-menopausal women with ER+/HER2- ABC.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 29,
      "from": 19,
      "beatId": "a90ff87c-6a94-47ae-8622-c8e4ab68f4ea",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "SERENA-2 trial data and conclusions",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}